Effect of low-to-moderate dose glucocorticoids on viral clearance in COVID-19: a retrospective study
10.3760/cma.j.issn.1674-2397.2020.01.005
- VernacularTitle:中低剂量糖皮质激素影响新型冠状病毒清除时间的回顾性研究
- Author:
Qin NI
1
;
Cheng DING
;
Yongtao LI
;
Hong ZHAO
;
Jun LIU
;
Xuan ZHANG
;
Yanfei CHEN
;
Yongzheng GUO
;
Liang YU
;
Hongzhen JU
;
Jingjing TAO
;
Ping YI
;
Guanjing LANG
;
Junwei SU
;
Ding SHI
;
Wenrui WU
;
Xiaoxin WU
;
Ling YU
;
Jifang SHENG
;
Kaijin XU
Author Information
1. 浙江大学医学院附属第一医院传染病诊治国家重点实验室、国家感染性疾病临床医学研究中心、感染性疾病诊治协同创新中心，杭州 310003
- From:
Chinese Journal of Clinical Infectious Diseases
2020;13(1):21-24
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the effect of low-to-moderate dose glucocorticoid therapy on viral clearance in patients with COVID-19.Methods:A total of 72 patients diagnosed with COVID-19 from January 19 to February 17, 2020 at the First Affiliated Hospital, Zhejiang University School of Medicine were recruited. All patients received oral arbidol and combination of lopinavir/ritonavir or darunavir/cobistitat for antiviral therapy, and symptomatic supportive care. Among them, 51 patients received methylprednisolone (0.75-1.50 mg·kg -1·d -1) (glucocorticoid treatment group), and 21 patients did not use glucocorticoid (control group). The time of virologic negative conversion in sputum and the time of radiologic recovery in lung since onset were compared between the two groups. The Kruskal-Wallis test or Fisher exact test was used to compare the difference between groups. Results:The median ages of the glucocorticoid group and the control group were 52 (45, 62) and 46 (32, 56) years ( χ2=4.365, P<0.05). The clinical conditions at hospital admission were different between the two groups ( P<0.01). The severe cases accounted for 52.0%, while moderate cases in the control group accounted for 71.4%. The median times from the onset to virologic negative conversion in the two groups were 15 (13, 20) and 14 (12, 20) days ( P>0.05). The median times from onset to radiologic recovery were 13 (11, 15) and 13 (12, 17) days in the two groups ( P>0.05). In moderate cases, the median times from the onset to virologic conversion in sputum were 13 (11, 18) days in the glucocorticoid group and 13 (12, 15) days in the control group ( P>0.05). The median times from onset to radiologic recovery in lung were 12 (10, 15) and 13 (12, 17) days, respectively ( P>0.05). Conclusions:Low-to-moderate glucocorticoid treatment has no effect on the time of virus clearance in patients with different clinical types of COVID-19, and also no effect on accelerating radiologic recovery in lung, so it is not recommended.
